As a consequence, the design of CA inhibitors (CAIs) is a highly dynamic field of medicinal chemistry. Due to the therapeutic potential of thiadiazoles as CAIs, new 1,3,4-thiadiazole derivatives were synthesized and investigated for their inhibitory effects on hCA I and hCA II. Although the tested compounds did not carry a sulfonamide group, an important pharmacophore for CA inhibitory activity, it was
                                    近年来,抑制
碳酸酐酶(CA)已成为一种对多种疾病(例如青光眼,癫痫,肥胖症和癌症)进行药物干预的有前途的方法。结果,CA
抑制剂(CAI)的设计是药物
化学的高度动态领域。由于
噻二唑具有作为CAI的治疗潜力,因此合成了新的1,3,4-
噻二唑衍
生物并研究了它们对hCA I和hCA II的抑制作用。尽管所测试的化合物不带有
磺胺基团,这是CA抑制活性的重要药效团,但一个令人惊奇的发现是,它们中的大多数对hCA的作用均优于参考试剂
乙酰唑胺(
AAZ)。在这些化合物中,N发现'-((5-(4-
氯苯基)
呋喃-2-基)亚甲基)-2-((5-(苯基
氨基)-1,3,4-
噻二唑-2-基)
硫代)乙酰
肼(3)是hCA I上最有效的化合物,IC 50值为0.14 nM,而N '-((5-(2-
氯苯基)
呋喃-2-基)亚甲基)-2-((5-(苯基
氨基)-发现1,3,4-
噻二唑-2-基)
硫基)乙酰
肼(1)是hCA II上最有效的化合物,IC